A Phase 2 interventional study of 3,4-methylenedioxymethamphetamine (125 mg) and 3,4-methyelendioxymethamphetamine (25 mg) in Posttraumatic Stress Disorder, sponsored by Lykos Therapeutics. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-15.
Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.
Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 26th largest by enrollment, is the only one that started in 2006, is one of 28 in phase 2, and was the 2nd registered.
2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 21–70
Sunstone Medical · Sites in United States
Ages 18+
Sheba Medical Center · Sites in Israel
Ages 18–75
Johns Hopkins University · Sites in United States
Ages 21+
Bronx VA Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 30 · Phase 3 6
First in 2004; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 69 across 2,202 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 25 across the 38 interventional studies. Of the 22 that completed or were terminated, 16 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lykos Therapeutics, one of the names counted as Resilient Pharmaceuticals. Under that name alone:
Lykos Therapeutics is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
20 studies in Stress Disorders, Post-Traumatic by Resilient Pharmaceuticals: none open now, none under way, none of them phase 3. Of 17 finished, 15 (88%) have results posted.
Among the 20 studies in Stress Disorders, Post-Traumatic by Resilient Pharmaceuticals, this one is the 9th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2006, is one of 13 in phase 2, and was the 2nd registered.
Resilient Pharmaceuticals’s Stress Disorders, Post-Traumatic studies by the year they started, since 2004.
4 of the studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06117306Phase 3Healing BreakthroughMDMA-assisted Massed Prolonged Exposure for PTSD | 2027-03 |
| NCT07569159Sunstone MedicalMDMA Therapy in Veterans With PTSD | 2027-04-01 |
| NCT05837845Patricia SuppesMDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder | 2027-05 |
| NCT05732155Guy SchusheimPreliminary Effectiveness of Hybrid Individual and Group MDMA-assisted Therapy for War-related PTSD | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Resilient Pharmaceuticals’s 20 in Stress Disorders, Post-Traumatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will examine MDMA-assisted psychotherapy in individuals aged 18 years or older diagnosed with PTSD, with PTSD symptoms not improving after trying at least one treatment. This objective of this study is to determine whether three eight-hour long sessions of MDMA-assisted psychotherapy, scheduled three to five weeks apart, can be safely administered to participants with PTSD, and whether combining a fully therapeutic dose of MDMA with psychotherapy, when compared with a low ("active placebo") dose of MDMA, will reduce PTSD symptoms. Participants will be randomly assigned to receive the full dose of MDMA (125 mg) or assigned to receive a low or "active placebo" dose of MDMA (25 mg) during each of three experimental sessions.
Posttraumatic stress disorder (PTSD) occurs after experiencing a traumatic event or events. PTSD is a public health problem that causes a great deal of suffering.
This study will examine MDMA-assisted psychotherapy in individuals aged 18 years or older diagnosed with PTSD, with PTSD symptoms not improving after trying at least one treatment. This objective of this study is to determine whether three eight-hour long sessions of MDMA-assisted psychotherapy, scheduled three to five weeks apart, can be safely administered to participants with PTSD, and whether combining a fully therapeutic dose of MDMA with psychotherapy, when compared with a low ("active placebo") dose of MDMA, will reduce PTSD symptoms. Participants will be randomly assigned to receive the full dose of MDMA (125 mg) or assigned to receive a low or "active placebo" dose of MDMA (25 mg) during each of three experimental sessions.
People who receive the low dose of MDMA have the opportunity to take part in a second "open label" study continuation, wherein the participants will undergo three MDMA-assisted sessions, with the participant and the researchers knowing that a full dose of MDMA is being administered. People who receive the full dose of MDMA, and any person who received low-dose MDMA and does not undergo the open-label study continuation will have PTSD symptoms measured six and twelve months after the third session. People who take part in the open label study continuation have their PTSD symptoms assessed six and 12 months after the third Phase II MDMA-assisted session.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three 8-hour sessions of MDMA-assisted therapy with 125 mg of MDMA, followed by a supplemental dose of 62.5 mg MDMA
Drug: 3,4-methylenedioxymethamphetamine (125 mg) · Behavioral: Therapy
Three 8-hour sessions of MDMA-assisted therapy with 25 mg of MDMA, followed by a supplemental dose of 12.5 mg MDMA
Drug: 3,4-methyelendioxymethamphetamine (25 mg) · Behavioral: Therapy
Participants will receive an initial dose of 125 mg MDMA orally and, if investigator and participant deem appropriate, 2.5 hours later they will receive 62.5 mg MDMA orally.
Also known as: MDMA
Participants will receive a 25 mg MDMA orally, and if investigator and participant agree, 2.5 hours later they will receive 12.5 mg MDMA orally.
Also known as: MDMA
Non-directive therapy performed by a team of two co-therapists
Change From Baseline to Primary Endpoint in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV)
The CAPS-IV is a structured clinical interview designed to assess the symptoms and severity of PTSD. The CAPS-IV provides a means to evaluate the frequency and intensity dimensions of each symptom, the impact of symptoms on the patient's social and occupational functioning, the overall severity of the symptom complex, global improvement since baseline, and the validity of the ratings obtained. Total severity scores range from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
Time frame: Less than 4 weeks before first experimental session (Baseline) to 3 weeks post 3rd experimental session (Primary Endpoint)
Change From Baseline to Primary Endpoint in Posttraumatic Stress Diagnostic Scale (PDS)
The Posstraumatic Stress Diagnostic Scale (PSD) is a 49-item self-report instrument to aid in the diagnosis of PTSD. Questions are asked about symptoms experienced and participants respond on a scale from 0 ("not at all or only one time") to 3 ("5 or more times a week/almost always"). Items are summed to create a total score that ranges from 0 to 51, with higher scores indicating more PTSD symptoms.
Time frame: Less than 4 weeks before first experimental session (Baseline) to 3 weeks post 3rd experimental session (Primary Endpoint)
Participants were recruited by calling for referrals from psychiatric hospitals, trauma counseling centers, psychiatrists and psychotherapists in the German-speaking part of Switzerland.
| Milestone | Full Dose MDMA-assisted Therapy (125 mg Stage 1) | Active Placebo MDMA-assisted Therapy (25 mg Stage 1) | Full Dose MDMA-assisted Therapy (125 mg Stage 2) | Full or Larger Dose MDMA-assisted Therapy (125 or 150 mg Stage 3) |
|---|---|---|---|---|
| Started | 9 | 5 | 0 | 0 |
| Completed stage 2 | 0 | 0 | 4 | 0 |
| Completed stage 3 | 0 | 0 | 0 | 3 |
| Completed | 8 | 5 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 0 |
The CAPS-IV is a structured clinical interview designed to assess the symptoms and severity of PTSD. The CAPS-IV provides a means to evaluate the frequency and intensity dimensions of each symptom, the impact of symptoms on the patient's social and occupational functioning, the overall severity of the symptom complex, global improvement since baseline, and the validity of the ratings obtained. Total severity scores range from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
| score on a scale | Full Dose MDMA-assisted Therapy (125 mg) | Active Placebo MDMA-assisted Therapy (25 mg) |
|---|---|---|
| Change From Baseline to Primary Endpoint in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) | -15.6 ± 18.1 | 3.3 ± 15.3 |
The Posstraumatic Stress Diagnostic Scale (PSD) is a 49-item self-report instrument to aid in the diagnosis of PTSD. Questions are asked about symptoms experienced and participants respond on a scale from 0 ("not at all or only one time") to 3 ("5 or more times a week/almost always"). Items are summed to create a total score that ranges from 0 to 51, with higher scores indicating more PTSD symptoms.
| score on a scale | Full Dose MDMA-assisted Therapy (125 mg) | Active Placebo MDMA-assisted Therapy (25 mg) |
|---|---|---|
| Change From Baseline to Primary Endpoint in Posttraumatic Stress Diagnostic Scale (PDS) | -8.6 ± 13.0 | 7.3 ± 6.2 |
Collected over From baseline to end of Stage 3 (approximately 1 year). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Full Dose MDMA-assisted Therapy (125 mg Stage 1) | 0/9 (0%) | 2/9 (22.2%) | 8/9 (88.9%) |
| Active Placebo MDMA-assisted Therapy (25 mg Stage 1) | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Full Dose MDMA-assisted Therapy (125 mg Stage 2) | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Full or Larger Dose MDMA-assisted Therapy (125 or 150 mg Stage 3) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Event | Full Dose MDMA-assisted Therapy (125 mg Stage 1) | Active Placebo MDMA-assisted Therapy (25 mg Stage 1) | Full Dose MDMA-assisted Therapy (125 mg Stage 2) | Full or Larger Dose MDMA-assisted Therapy (125 or 150 mg Stage 3) |
|---|---|---|---|---|
| Metasteses to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/9 | 0/5 | 0/4 | 0/3 |
| Suicidal behaviorPsychiatric disorders | 1/9 | 0/5 | 0/4 | 0/3 |
| Event | Full Dose MDMA-assisted Therapy (125 mg Stage 1) | Active Placebo MDMA-assisted Therapy (25 mg Stage 1) | Full Dose MDMA-assisted Therapy (125 mg Stage 2) | Full or Larger Dose MDMA-assisted Therapy (125 or 150 mg Stage 3) |
|---|---|---|---|---|
| AnxietyPsychiatric disorders | 4/9 | 1/5 | 0/4 | 0/3 |
| FatigueGeneral disorders | 1/9 | 2/5 | 1/4 | 1/3 |
| Angina tonsillitusInfections and infestations | 0/9 | 0/5 | 0/4 | 1/3 |
| HeadacheNervous system disorders | 1/9 | 1/5 | 1/4 | 0/3 |
| InsomniaPsychiatric disorders | 2/9 | 1/5 | 1/4 | 0/3 |
| Iron deficiency AnemiaMetabolism and nutrition disorders | 0/9 | 0/5 | 1/4 | 0/3 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/9 | 0/5 | 1/4 | 0/3 |
| Neck painMusculoskeletal and connective tissue disorders | 0/9 | 0/5 | 1/4 | 0/3 |
| Urinary tract infectionInfections and infestations | 0/9 | 0/5 | 1/4 | 0/3 |
| Depressed moodPsychiatric disorders | 2/9 | 0/5 | 0/4 | 0/3 |
| Age, Continuous(years) | Full Dose MDMA-assisted Therapy (125 mg) | Active Placebo MDMA-assisted Therapy (25 mg) | Total |
|---|---|---|---|
| Mean | 42.1 ± 12.8 | 40.0 ± 6.2 | 41.4 ± 11.2 |
| Sex: Female, Male(Participants) | Full Dose MDMA-assisted Therapy (125 mg) | Active Placebo MDMA-assisted Therapy (25 mg) | Total |
|---|---|---|---|
| Female | 7 | 3 | 10 |
| Male | 1 | 1 | 2 |
| Race and Ethnicity Not Collected(Participants) | Full Dose MDMA-assisted Therapy (125 mg) | Active Placebo MDMA-assisted Therapy (25 mg) | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Country of origin(Participants) | Full Dose MDMA-assisted Therapy (125 mg) | Active Placebo MDMA-assisted Therapy (25 mg) | Total |
|---|---|---|---|
| Switzerland | 7 | 4 | 11 |
| France | 1 | 0 | 1 |
| Work status(Participants) | Full Dose MDMA-assisted Therapy (125 mg) | Active Placebo MDMA-assisted Therapy (25 mg) | Total |
|---|---|---|---|
| On disability | 4 | 1 | 5 |
| Fit for limited employment | 2 | 1 | 3 |
| Working full-time | 1 | 2 | 3 |
| Retired | 1 | 0 | 1 |
| Duration of PTSD(years) | Full Dose MDMA-assisted Therapy (125 mg) | Active Placebo MDMA-assisted Therapy (25 mg) | Total |
|---|---|---|---|
| Mean | 16.4 ± 10.9 | 22.3 ± 12.1 | 18.3 ± 12.0 |
| Duration of prior therapy(months) | Full Dose MDMA-assisted Therapy (125 mg) | Active Placebo MDMA-assisted Therapy (25 mg) | Total |
|---|---|---|---|
| Mean | 39.9 ± 73.3 | 123 ± 60.6 | 85.8 ± 71.4 |
| On medication for PTSD at enrollment(Participants) | Full Dose MDMA-assisted Therapy (125 mg) | Active Placebo MDMA-assisted Therapy (25 mg) | Total |
|---|---|---|---|
| Yes | 4 | 2 | 6 |
| No | 4 | 2 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2006 to primary completion in Sep 2009, 35 months.
Results were first posted in Sep 2021, 12 years after primary completion. A results delay was requested in Jul 2011.
Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 35 months is above that.
Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine
Stress Disorders, Post-Traumatic →